Overview

Ribavirin, Its Dosing Regime

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the medicines for chronic hepatitis C can be taken once daily, instead of twice daily.
Phase:
Phase 4
Details
Lead Sponsor:
Maastricht University Medical Center
Collaborator:
Roche Pharma AG
Treatments:
Ribavirin